Insmed Inc INSM
We take great care to ensure that the data presented and summarized in this overview for INSMED Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding INSM
View all-
Vanguard Group Inc Valley Forge, PA17.1MShares$1.27 Billion0.02% of portfolio
-
Black Rock Inc. New York, NY14.3MShares$1.06 Billion0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD12.6MShares$932 Million0.11% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y910.5MShares$778 Million62.32% of portfolio
-
Capital International Investors Los Angeles, CA6.52MShares$483 Million0.09% of portfolio
-
State Street Corp Boston, MA6.18MShares$458 Million0.02% of portfolio
-
Baker Bros. Advisors LP New York, NY4.42MShares$327 Million3.45% of portfolio
-
Geode Capital Management, LLC Boston, MA3.81MShares$283 Million0.02% of portfolio
-
Pictet Asset Management Sa Geneva 73, V83.7MShares$274 Million0.09% of portfolio
-
Jpmorgan Chase & CO New York, NY3.31MShares$245 Million0.02% of portfolio
Latest Institutional Activity in INSM
Top Purchases
Top Sells
About INSM
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Insider Transactions at INSM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 16
2024
|
Martina M.D. Flammer Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
13,436
-11.24%
|
$994,264
$74.92 P/Share
|
|
Sep 16
2024
|
Martina M.D. Flammer Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,436
+10.1%
|
$456,824
$34.03 P/Share
|
|
Sep 13
2024
|
Martina M.D. Flammer Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
26,969
-20.26%
|
$1,995,706
$74.9 P/Share
|
|
Sep 13
2024
|
Martina M.D. Flammer Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
26,969
+16.85%
|
$916,946
$34.03 P/Share
|
|
Sep 13
2024
|
Michael Alexander Smith Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
27,871
-15.71%
|
$2,062,454
$74.46 P/Share
|
|
Sep 13
2024
|
Michael Alexander Smith Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+6.81%
|
$154,000
$22.76 P/Share
|
|
Sep 12
2024
|
Martina M.D. Flammer Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
635
-0.59%
|
$46,990
$74.92 P/Share
|
|
Sep 12
2024
|
Martina M.D. Flammer Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
635
+0.59%
|
$21,590
$34.03 P/Share
|
|
Sep 10
2024
|
Orlov S Nicole Schaeffer Chief People Strategy Officer |
SELL
Open market or private sale
|
Direct |
37,575
-14.53%
|
$2,667,825
$71.63 P/Share
|
|
Sep 10
2024
|
Orlov S Nicole Schaeffer Chief People Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
37,575
+21.44%
|
$375,750
$10.85 P/Share
|
|
Sep 06
2024
|
Martina M.D. Flammer Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
149,002
-24.45%
|
$10,579,142
$71.65 P/Share
|
|
Sep 06
2024
|
Martina M.D. Flammer Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
149,002
+11.49%
|
$3,278,044
$22.72 P/Share
|
|
Aug 29
2024
|
Melvin Md Sharoky Director |
BUY
Bona fide gift
|
Indirect |
10,000
+36.08%
|
-
|
|
Aug 29
2024
|
Melvin Md Sharoky Director |
SELL
Bona fide gift
|
Direct |
10,000
-3.24%
|
-
|
|
Aug 12
2024
|
Orlov S Nicole Schaeffer Chief People Strategy Officer |
SELL
Open market or private sale
|
Direct |
9,469
-8.64%
|
$681,768
$72.49 P/Share
|
|
Aug 12
2024
|
Michael Alexander Smith Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
88,070
-28.49%
|
$6,429,110
$73.2 P/Share
|
|
Aug 12
2024
|
Michael Alexander Smith Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
88,070
+16.52%
|
$1,409,120
$16.05 P/Share
|
|
Jul 08
2024
|
Michael Alexander Smith Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
730
-0.82%
|
$51,100
$70.05 P/Share
|
|
Jun 10
2024
|
Martina M.D. Flammer Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
21,195
-16.65%
|
$1,271,700
$60.0 P/Share
|
|
Jun 10
2024
|
Martina M.D. Flammer Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,195
+14.27%
|
$487,485
$23.75 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 346K shares |
|---|---|
| Exercise of conversion of derivative security | 1M shares |
| Bona fide gift | 13.6K shares |
| Open market or private sale | 1.14M shares |
|---|---|
| Payment of exercise price or tax liability | 730 shares |
| Bona fide gift | 13.6K shares |